Citigroup Inc Edgewise Therapeutics, Inc. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 36,944 shares of EWTX stock, worth $679,030. This represents 0.0% of its overall portfolio holdings.

Number of Shares

36,944

Previous 7,261 408.8%

Holding current value

$679,030

Previous $79,000 751.9%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$9.25 - $19.97 $274,567 - $592,769	29,683 Added 408.8%	36,944 $673,000
Q4 2023 Feb 09, 2024	BUY	$5.51 - $12.1 $33,517 - $73,604	6,083 Added 516.38%	7,261 $79,000
Q3 2023 Nov 09, 2023	SELL	$5.73 - $7.69 $75,108 - $100,800	-13,108 Reduced 91.75%	1,178 $6,000
Q2 2023 Aug 10, 2023	BUY	$5.71 - $10.29 $77,467 - $139,604	13,567 Added 1886.93%	14,286 $110,000
Q1 2023 May 11, 2023	SELL	$6.66 - $11.33 $1,358 - $2,311	-204 Reduced 22.1%	719 $4,000

Q4 2022 Feb 09, 2023	SELL	$7.58 - $11.08 $1,068 - $1,562	-141 Reduced 13.25%	923 $8,000
Q3 2022 Nov 10, 2022	SELL	$8.08 - $13.58 $15,747 - $26,467	-1,949 Reduced 64.69%	1,064 $10,000
Q2 2022 Aug 10, 2022	BUY	$5.67 - $9.87 $3,186 - $5,546	562 Added 22.93%	3,013 $24,000
Q1 2022 May 12, 2022	SELL	$9.1 - $18.97 $80,853 - $168,548	-8,885 Reduced 78.38%	2,451 $24,000
Q4 2021 Feb 10, 2022	BUY	$14.41 - $22.41 $141,779 - $220,491	9,839 Added 657.25%	11,336 $173,000
Q3 2021 Nov 10, 2021	BUY	$14.11 - $24.1 $21,122 - $36,077	1,497 New	1,497 $25,000

Others Institutions Holding EWTX

# of Institutions

129

Shares Held

76.3M

Call Options Held

14.7K

Put Options Held

14.8K

View Full List

About Edgewise Therapeutics, Inc.

Ticker EWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,171,700
Market Cap $1.16B
Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...

More about EWTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account